ALPORT SYNDROME
Clinical trials for ALPORT SYNDROME explained in plain language.
Never miss a new study
Get alerted when new ALPORT SYNDROME trials appear
Sign up with your email to follow new studies for ALPORT SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Kidney hope: drug combo may slow alport disease
Disease control CompletedThis completed Phase 4 trial tested two drugs—dapagliflozin and spironolactone—alone and together in 12 adults with Alport syndrome, a genetic kidney disease. The goal was to see if these drugs could lower protein levels in urine, a key sign of kidney damage. Participants took ea…
Matched conditions: ALPORT SYNDROME
Phase: PHASE4 • Sponsor: Stefan Lujinschi • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug aims to protect kidneys in rare genetic disease
Disease control CompletedThis study tested a new drug, setanaxib, in 20 people with Alport syndrome, a genetic condition that damages kidneys. The goal was to see if the drug is safe and can help preserve kidney function when added to standard care. Participants took either setanaxib or a placebo for 24 …
Matched conditions: ALPORT SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: Calliditas Therapeutics AB • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Could a malaria drug help kids with a rare kidney disease?
Disease control CompletedThis study tested whether hydroxychloroquine, a drug used for malaria and autoimmune conditions, can safely reduce blood and protein in the urine of children with X-linked Alport syndrome, a genetic kidney disease. Fifty children aged 3 to 18 with stable kidney function took the …
Matched conditions: ALPORT SYNDROME
Phase: PHASE2 • Sponsor: Shanghai Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Experimental drug targets genetic cause of alport syndrome in tiny pilot
Disease control CompletedThis phase 2 pilot study tested a drug called ELX-02 in 3 adults with Alport syndrome caused by specific 'nonsense' mutations. The goal was to see if the drug is safe and if it can reduce protein in the urine, a sign of kidney damage. Participants received daily injections for 8 …
Matched conditions: ALPORT SYNDROME
Phase: PHASE2 • Sponsor: Eloxx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New drug shows promise for slowing kidney disease in alport syndrome
Disease control CompletedThis study tested a drug called vonafexor in 26 people with Alport syndrome, a genetic condition that damages kidneys. The goal was to see if the drug is safe and if it can help protect kidney function. Participants took increasing doses over 24 weeks. The study is now complete, …
Matched conditions: ALPORT SYNDROME
Phase: PHASE2 • Sponsor: Enyo Pharma • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New hope for kidney patients: experimental drug targets protein leak
Disease control CompletedThis study tested an experimental drug called R3R01 in 43 people with two rare kidney diseases (Alport syndrome and focal segmental glomerulosclerosis) whose protein in urine remained high despite standard treatment. The main goals were to check safety and see if the drug could r…
Matched conditions: ALPORT SYNDROME
Phase: PHASE2 • Sponsor: River 3 Renal Corp. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Alport syndrome registry opens doors for future therapies
Knowledge-focused CompletedThis study created a registry of 655 people and families with Alport syndrome to collect health information over time. The goal is to better understand how the disease progresses and to provide a foundation for testing new treatments. Participants simply share their medical histo…
Matched conditions: ALPORT SYNDROME
Sponsor: University of Minnesota • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC